Stocktoria
Nasus Pharma Ltd NSRX
Nasus Pharma Ltd (NSRX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.2B at a -0.5% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Manufacturing · percentile among 1829 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.538 |
| Retained earnings / assets | -3.701 |
| EBIT / assets | -0.98 |
| Equity / liabilities | 1.238 |
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
FAQ
Is NSRX financially healthy?
Nasus Pharma Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NSRX pay a dividend?
No, Nasus Pharma Ltd does not currently pay a dividend.
How profitable is NSRX?
In FY2025, Nasus Pharma Ltd had a net margin of -0.5% and a return on equity of -211.6%.
Source: SEC EDGAR filings · CIK 0002029039 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.